LUCEOME BIOTECHNOLOGIES, LLC
Biotech · Private
High-throughput kinase assays using split-luciferase system for Toxoplasma gondii drug discovery and screening
- Grants
- $7.1M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Kinome-wide Cell-Based Assays | $873,704 | |
| Federal grant | Department of Health and Human Services · Phase II · Kinome-wide Cell-Based Assays | $622,659 | |
| Federal grant | Department of Health and Human Services · Phase II · Tools for Accelerating R&D for Historically Understudied Protein Kinases | $708,631 | |
| Federal grant | Department of Health and Human Services · Phase II · Tools for Accelerating R&D for Historically Understudied Protein Kinases | $699,809 | |
| Federal grant | Department of Health and Human Services · Phase I · Enabling Toxoplasma gondii Kinome Directed Drug Discovery | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Kinase Targeted Antimalarial Agents | $957,654 | |
| Federal grant | Department of Health and Human Services · Phase II · Kinase Targeted Antimalarial Agents | $798,586 | |
| Federal grant | Department of Health and Human Services · Phase I · Split-luciferase Epigenetic Assays for Drug Discovery | $240,429 | |
| Federal grant | Department of Health and Human Services · Phase II · Enabling Toxoplasma gondii Kinome Directed Drug Discovery | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Enabling Toxoplasma gondii Kinome Directed Drug Discovery | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2737 | LUNA BIOSCIENCE, INC. | — | — |
| 2738 | DFH Pharma, Inc | — | — |
| 2739 | MIXEDLCMEDIA LLC | — | — |
| 2740 | LUCEOME BIOTECHNOLOGIES, LLC | — | — |
| 2741 | PROTEIN ENGINES LLC | — | — |
| 2742 | AVOLYNT, INC. | — | — |
| 2743 | TRIA BIOSCIENCE CORPORATION | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.